Oncotarget

Research Perspectives:

Melatonin and carcinogenesis in mice: the 50th anniversary of relationships

Vladimir N. Anisimov _ and Alexey G. Golubev

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2023; 14:972-976. https://doi.org/10.18632/oncotarget.28537

Metrics: PDF 248 views  |   Full Text 1997 views  |   ?  


Abstract

Vladimir N. Anisimov1,* and Alexey G. Golubev1,*

1 Department of Carcinogenesis and Oncogerontology, N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg 197758, Russia

* The authors contributed equally to this work

Correspondence to:

Vladimir N. Anisimov, email: [email protected]

Keywords: cancer; melatonin; mice

Received: November 07, 2023     Accepted: November 16, 2023     Published: December 12, 2023

Copyright: © 2023 Anisimov and Golubev. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The history of studies of melatonin effects on cancer in mice is outlined, the main lesson being that the systemic in vivo effects of melatonin on animals may overwhelm the in vitro effects found using tissue explants or cell cultures. In particular, the timing of melatonin administration is of crucial importance for using the drug, which is freely available over counter and thus needs no licensing for its applications in oncology.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28537